Westlake Chemical Partners LP clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Westlake Chemical Partners LP
WLKP · the NYSE · USD · Market cap $739M
Westlake Chemical Partners LP acquires, develops, and operates ethylene production facilities and related assets in the United States.
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price21.20 USD at the 13 Nov 2026 close
- Fair value20.83. Our model only; only one analyst covers it, too few to cross-check it.
- Our value readFair vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 3.42)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $20.83 to $23.95, base estimate $20.83 (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 3.42, read 2026-11-15
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Westlake Chemical Partners LP holds its Accumulation at $21.20. Consolidating, no directional conviction, held for 149 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 149 days |
| Price at the screen | $21.20 |
| Valuation | 12.78 trailing · 11.32 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.50 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.81% | Below 33% | Interest-bearing debt is just 31.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 4.25% | Below 49% | Money owed to the company is 4.2% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Westlake Chemical Partners LP clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Westlake Chemical Partners LP clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades above our $20.83 fair value estimate.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 1.8% above the base estimate.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $20.83, with a range of $20.83 to $23.95, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business. At the screened price it sits 2% above our $20.83 fair value: priced for the quality, not a bargain.
| Forward P/E | 11.3xreasonably valued |
| Trailing P/E | 12.8xreasonably valued |
| EPS, trailing | 1.64 |
| EPS, forward | 1.85 |
| Revenue growth | +0.0%revenue is shrinking |
| Profit margin | 4.7%barely profitable |
| Return on equity | 41.8%an exceptional return on shareholder capital |
| FCF yield | 37.20% |
| Dividend yield | 8.28% |
| Debt to equity | 0.52moderate, manageable leverage |
| Current ratio | 3.44comfortably covers its short-term bills |
| Beta | 0.50barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 17.75 - 23.88 |
| Market cap | $739M |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeWLKP trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Westlake Chemical Partners Q2 Earnings Call Highlights MarketBeat · 9 Aug 2026
- Westlake Chemical Partners Q2 Earnings Call Highlights Yahoo Finance · 9 Aug 2026
- Westlake Chemical Partners LP Q2 2026 Earnings Call Summary Moby · 5 Aug 2026
- Westlake Chemical Partners LP Q2 2026 Earnings Call Summary Yahoo Finance · 5 Aug 2026
- Westlake Chemical Partners LP (WLKP) (Q2 2026) Earnings Call Highlights: Stable Distributions ... GuruFocus.com · 5 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.25 | +0.2% | $0.47 | $1,022 | +2.2% |
| 2 months | $22.21 | +4.8% | $0.47 | $1,070 | +7.0% |
| 3 months | $22.28 | +4.5% | $0.47 | $1,066 | +6.6% |
| 6 months | $18.91 | +23.1% | $0.94 | $1,281 | +28.1% |
| 1 year | $20.38 | +14.2% | $1.88 | $1,235 | +23.5% |
| 2 years | $19.14 | +21.6% | $3.77 | $1,413 | +41.3% |
| 3 years | $17.12 | +35.9% | $5.65 | $1,689 | +68.9% |
| 5 years | $18.01 | +29.3% | $9.42 | $1,815 | +81.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever WLKP does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.